Diener HC, et al. - This multicenter, randomized, double-blind trial was conducted to find out the efficacy of dabigatran vs aspirin for the prevention of recurrent strokes in patients who previously had an embolic stroke of undetermined source. Total 5,390 patients were taken at 564 sites and out of them 2,695 patients were randomly assigned to receive a dose of dabigatran 150 mg or 110 mg twice daily and the rest of the 2,695 patients received aspirin at a dose of 100 mg once daily. Dabigatran did not prove to be more efficacious than aspirin in preventing recurrent stroke in patients with a recent history of embolic stroke of undetermined source. Clinically relevant nonmajor bleeding events were more common in the dabigatran group, but the incidence of major bleeding was not higher in the dabigatran group vs the aspirin group.